Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 May;57(5):935-9.
doi: 10.1007/s00125-014-3183-2. Epub 2014 Feb 20.

Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program

Geoffrey A Walford  1 , Yong Ma, Costas A Christophi, Ronald B Goldberg, Petr Jarolim, Edward Horton, Kieren J Mather, Elizabeth Barrett-Connor, Jaclyn Davis, Jose C Florez, Thomas J Wang; Diabetes Prevention Program Research Group
Collaborators, Affiliations
Randomized Controlled Trial

Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program

Geoffrey A Walford et al. Diabetologia. 2014 May.

Abstract

Aims/hypothesis: We aimed to study the relationship between measures of adiposity, insulin sensitivity and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the Diabetes Prevention Program (DPP).

Methods: The DPP is a completed clinical trial. Using stored samples from this resource, we measured BMI, waist circumference (WC), an insulin sensitivity index (ISI; [1/HOMA-IR]) and NT-proBNP at baseline and at 2 years of follow-up in participants randomised to placebo (n = 692), intensive lifestyle intervention (n = 832) or metformin (n = 887).

Results: At baseline, log NT-proBNP did not differ between treatment arms and was correlated with baseline log ISI (p < 0.0001) and WC (p = 0.0003) but not with BMI (p = 0.39). After 2 years of treatment, BMI decreased in the lifestyle and metformin groups (both p < 0.0001); WC decreased in all three groups (p < 0.05 for all); and log ISI increased in the lifestyle and metformin groups (both p < 0.001). The change in log NT-proBNP did not differ in the lifestyle or metformin group vs the placebo group (p > 0.05 for both). In regression models, the change in log NT-proBNP was positively associated with the change in log ISI (p < 0.005) in all three study groups after adjusting for changes in BMI and WC, but was not associated with the change in BMI or WC after adjusting for changes in log ISI.

Conclusion/interpretation: Circulating NT-proBNP was associated with a measure of insulin sensitivity before and during preventive interventions for type 2 diabetes in the DPP. This relationship persisted after adjustment for measures of adiposity and was consistent regardless of whether a participant was treated with placebo, intensive lifestyle intervention or metformin.

PubMed Disclaimer

Conflict of interest statement

Duality of interest

TJW has received assay or research support from Diasorin, Singulex, Siemens, Brahms and Critical Diagnostics, as well as consulting fees or honoraria from Diasorin, Singulex and Roche Diagnostics. PJ has received Grant/Research Support from Abbott, AstraZeneca, Beckman Coulter, Daiichi Sankyo, GlaxoSmithKline, Merck, Roche Diagnostics, Takeda, and Waters Technologies and Salary/Consulting fees from T2 Biosystems and Quanterix. All other authors declare that they have no duality of interest in relation to the study.

Figures

Fig. 1
Fig. 1
Modelling change in log of NT-proBNP from baseline to follow-up by change in log of ISI and change in BMI or change in WC. (a) The relationship (linear regression slopes and 95% CI) between change in log NT-proBNP and change in BMI (black circles) or log ISI (black triangles). (b) The relationship (linear regression slopes and 95% CI) between change in log NT-proBNP and change in WC (black circles) or log ISI (black triangles). The point estimates are similar across all treatment groups, suggesting that the relationship between change in log NT-proBNP and change in BMI, WC or log ISI are consistent regardless of the intervention. The 95% CIs for the relationship between change in NT-proBNP and BMI or WC crosses 0 in all treatment groups, demonstrating no statistically significant relationship. Predictors (change in log ISI, BMI and WC) are scaled by their SDs in all regression models. All models were adjusted for age; sex; ethnicity; and baseline log NT-proBNP, log ISI and BMI or WC
Fig. 1
Fig. 1
Modelling change in log of NT-proBNP from baseline to follow-up by change in log of ISI and change in BMI or change in WC. (a) The relationship (linear regression slopes and 95% CI) between change in log NT-proBNP and change in BMI (black circles) or log ISI (black triangles). (b) The relationship (linear regression slopes and 95% CI) between change in log NT-proBNP and change in WC (black circles) or log ISI (black triangles). The point estimates are similar across all treatment groups, suggesting that the relationship between change in log NT-proBNP and change in BMI, WC or log ISI are consistent regardless of the intervention. The 95% CIs for the relationship between change in NT-proBNP and BMI or WC crosses 0 in all treatment groups, demonstrating no statistically significant relationship. Predictors (change in log ISI, BMI and WC) are scaled by their SDs in all regression models. All models were adjusted for age; sex; ethnicity; and baseline log NT-proBNP, log ISI and BMI or WC
See this image and copyright information in PMC

References

    1. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594–600. - PubMed
    1. Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation. 2005;112:2163–2168. - PubMed
    1. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation. 2007;115:1345–1353. - PubMed
    1. Magnusson M, Jujic A, Hedblad B, et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmö Diet and Cancer Study. The Journal of Clinical Endocrinology and Metabolism. 2012;97:638–645. - PMC - PubMed
    1. Lazo M, Young JH, Brancati FL, et al. NH2-terminal pro-brain natriuretic peptide and risk of diabetes. Diabetes. 2013;62:3189–3193. - PMC - PubMed

Publication types